Fatma Onmus

Clinical Bioinformatician

  • Current Role

    Current Role

    As a clinical bioinformation for the Clinical and Translational Research Informatics Branch, I’m responsible for the oversight of the CIDC part of the CIMAC-CIDC network (CIDC being the “Cancer Immunologic Data Commons,” while CIMAC stands for “Cancer Immune Monitoring and Analysis Centers”). This network addresses the critical importance of improving the management of cancer patients receiving immunotherapy by identifying biomarkers for optimizing immunotherapeutic strategies. The CIMAC-CIDC network involves a collaborative effort among various stakeholders, such as NCI, Clinical Trial Teams, CIMACs, the Partnership for Accelerating Cancer Therapies collaboration, and Foundation NIH. Together, we can collect, analyze, and share the data from various clinical trials that use analytically validated and standardized platforms.

  • Projects

    Projects

    Enables you to analyze a variety of clinical, specimen, and molecular data for biomarker discovery.
    Enrolls patients to determine whether treating cancer based on their genome is effective.
  • Publications
  • Background

    Background

    Education

    • Graduate Certificate Bioinformatics, University of Maryland Global Campus
    • M.S., Biology, Ege Üniversitesi (Turkey)
    • B.S., Biology, Ege Üniversitesi  (Turkey)

    Previous Work

    • Biologist, U.S. Department of Health and Human Services, Food and Drug Administration (FDA)
    • Senior Scientific Computer Engineer, Science Applications International Corporation
    • Bioinformatician, Contractor for Walter Reed Army Institute of Research
    • Research Associate/Lab Manager, J. Craig Venter Institute
    • Supervisor/Project Manager, Gene Logic
    • Associate Scientist, Metrigenix
    • Associate Scientist, Digene Corporation

    Recent Awards

    • 2024 FDA CDRH Excellence in Communications and Education Award, for exceptional leadership in advancing Artificial Intelligence (AI) training for reviewers and others interested in AI to help dive consistent understanding communication and collaboration.
    • 2024 FDA CDRH Excellence in Communications and Education Award, for exceptional leadership in advancing Digital Health review training, consistent policy implementation, and cross-Office communication and collaboration.
    • 2022 FDA Commissioner’s Special Citation (Paige Prostate De Novo Review Team), for excellent collaboration and coordination that led to the authorization of the first artificial intelligence-based software in digital pathology